Suppr超能文献

在印度新冠疫情期间,如何采用优先排序方法治疗血液系统疾病?

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

作者信息

Jain Arihant, Singh Charanpreet, Dhawan Rishi, Jindal Nishant, Mohindra Ritin, Lad Deepesh, Prakash Gaurav, Khadwal Alka, Suri Vikas, Bhalla Ashish, Kumari Savita, Varma Neelam, John M Joseph, Mahapatra Manoranjan, Malhotra Pankaj

机构信息

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.

Department of Hematology, All India Institute of Medical Education and Research, New Delhi, India.

出版信息

Indian J Hematol Blood Transfus. 2020 Oct;36(4):605-615. doi: 10.1007/s12288-020-01300-0. Epub 2020 Jun 6.

Abstract

The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.

摘要

目前已知大流行的冠状病毒SARS-CoV-2会在患有合并症的患者中引起严重感染(COVID-19),尤其是癌症患者或免疫抑制状态患者。如果疫情进入社区传播阶段,该国大多数医疗系统可能很快不堪重负。目前,关于在COVID-19大流行期间管理血液系统疾病患者的证据有限。本综述总结了临床医生可能面临的潜在挑战、指导决策的关键考虑因素以及应对预期挑战的可能解决方案。针对我们医疗环境中可行的大多数血液系统疾病,提出了针对特定疾病的建议和可能的决策指导。它并非旨在取代个人临床判断,而是提供一个制定地方政策的模板。

相似文献

1
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
Indian J Hematol Blood Transfus. 2020 Oct;36(4):605-615. doi: 10.1007/s12288-020-01300-0. Epub 2020 Jun 6.
2
3
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Med J Aust. 2020 Jun;212(10):481-489. doi: 10.5694/mja2.50607. Epub 2020 May 13.
5
A Reminder of Skin Cancer During the COVID-19 Pandemic.
Acta Dermatovenerol Croat. 2021 Apr;291(1):58.
6
COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals.
Expert Rev Hematol. 2020 Oct;13(10):1081-1092. doi: 10.1080/17474086.2020.1819785. Epub 2020 Sep 15.
8
9
COVID-19 in hematology: data from a hematologic and transplant unit.
Hematol Transfus Cell Ther. 2020 Oct-Dec;42(4):293-299. doi: 10.1016/j.htct.2020.08.004. Epub 2020 Sep 6.

引用本文的文献

1
Factors influencing treatment decision-making for cancer patients in low- and middle-income countries: A scoping review.
Cancer Med. 2023 Sep;12(17):18133-18152. doi: 10.1002/cam4.6375. Epub 2023 Aug 1.
2
Indian Society of Hematology and Blood Transfusion (ISHBT) Consensus Document on Hematological Practice During COVID-19 Pandemic.
Indian J Hematol Blood Transfus. 2021 Jan;37(1):1-9. doi: 10.1007/s12288-021-01405-0. Epub 2021 Feb 16.
3
The impact of biosafety enhancement on stat laboratory quality metrics: Lessons from the COVID-19 pandemic.
Clin Chim Acta. 2021 Jan;512:58-62. doi: 10.1016/j.cca.2020.11.021. Epub 2020 Dec 4.

本文引用的文献

2
Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
Med J Aust. 2020 Jun;212(10):481-489. doi: 10.5694/mja2.50607. Epub 2020 May 13.
3
Cancer Management in India during Covid-19.
N Engl J Med. 2020 May 14;382(20):e61. doi: 10.1056/NEJMc2011595. Epub 2020 Apr 28.
4
Thrombosis management in times of COVID-19 epidemy; a Dutch perspective.
Thromb J. 2020 Apr 20;18:7. doi: 10.1186/s12959-020-00220-3. eCollection 2020.
5
Palliative care and the COVID-19 pandemic.
Lancet. 2020 Apr 11;395(10231):1168. doi: 10.1016/S0140-6736(20)30822-9.
7
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?
Ecancermedicalscience. 2020 Mar 30;14:1023. doi: 10.3332/ecancer.2020.1023. eCollection 2020.
8
COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.
JCO Glob Oncol. 2020 Apr;6:557-559. doi: 10.1200/GO.20.00097.
9
Communication Skills in the Age of COVID-19.
Ann Intern Med. 2020 Jun 2;172(11):759-760. doi: 10.7326/M20-1376. Epub 2020 Apr 2.
10
Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.
Ann Oncol. 2020 Jul;31(7):894-901. doi: 10.1016/j.annonc.2020.03.296. Epub 2020 Mar 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验